hVEGF-IN-1 is primarily used in research settings to study angiogenesis, the process of new blood vessel formation. It acts as an inhibitor of vascular endothelial growth factor (VEGF), which plays a critical role in promoting angiogenesis. By blocking VEGF signaling, hVEGF-IN-1 helps researchers understand the mechanisms of diseases driven by abnormal blood vessel growth, such as cancer, macular degeneration, and certain inflammatory conditions. It is also utilized in preclinical studies to evaluate the potential of anti-angiogenic therapies, providing insights into the development of targeted treatments for these diseases.